All In Biotech

NDA 218275 · Istx

Zevtera

Ceftobiprole Medocaril Sodium · Intravenous

NovelPriority review

CDER novel approval, Apr 3, 2024: To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Apr 3, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

24

11 Phase 3, 0 recruiting

FAERS reports

57

55 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 13, 2026.

ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). 1.1 Staphylococcus aureus Bloodstream Infection (Bacteremia) ZEVTERA is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infection (bacteremia) (SAB), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates . 1.2 Acute Bacterial Skin and Skin Structure Infections ZEVTERA is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following gram-positive and gram-negative microorganisms: Staphylococcus aureus (methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes, and Klebsiella pneumoniae. 1.3 Community-Acquired Bacterial Pneumonia ZEVTERA is indicated for the treatment of adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following gram-positive and gram-negative microorganisms: Staphylococcus aureus (methicillin-susceptible isolates), Streptococcus...

Mechanism: ZEVTERA is an antibacterial drug [see Microbiology (12.4) ]

Therapeutic areas: Infectious disease and vaccines · Dermatology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 3, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • ZEVTERA · CEFTOBIPROLE MEDOCARIL SODIUM 667MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ceftobiprole Medocaril" as an intervention, any sponsor and status, largest first.

All 24 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use12
  • epilepsy10
  • torsade de pointes6
  • alveolar lung disease5
  • gangrene5
  • pneumonia necrotising5
  • rash5
  • agitation3
  • clostridium difficile infection3
  • diarrhoea3
  • pancytopenia3
  • pruritus3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
201810
20191
20211
20243
202519
202622

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Istx

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.